Eric Rowinsky
CMO, United States BioCity Biopharma
Seminars
Tuesday 4th November 2025
BC3195, a Novel ADC Targeting CDH3 (Cadherin-3): Exploring Preliminary Clinical Study Results
3:00 pm
- Covering the rationale for using ADC constructs targeting cadherin-3 (CDH3) which are overexpressed in a wide range of solid cancers
- Reviewing the preclinical performance of BC3195 and the importance of non-clinical studies in developing, a first- in-class CDH3-targeting ADC
- Reviewing the preliminary results of clinical studies of BC3195
